Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2/3 1Phase 2 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 39NIH 3INDUSTRY 3UNKNOWN 2NETWORK 2

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Rectal Neoplasms 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1

Interventions

pembrolizumab 1029Carboplatin 966Paclitaxel 941Gemcitabine 798Cisplatin 754Docetaxel 697Bevacizumab 638Nivolumab 519Pemetrexed 507Capecitabine 475Cyclophosphamide 468Fluorouracil 424Dexamethasone 409Rituximab 391Oxaliplatin 351Injections 344Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 288Irinotecan 269130-nm albumin-bound paclitaxel 255Prednisone 250Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 215durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × raltitrexed × Clear all
NCT01959061 2017-03-13

TACE

Nanjing Chia-tai Tianqing Pharmaceutical

Phase 4 Unknown
320 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

NCT00590278 2008-01-25

TOMUDEX

AstraZeneca

Phase 2 Completed
49 enrolled
Gastrointestinal

Rectal Neoplasms

NCT00234429 2007-12-18

A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma

AstraZeneca

Phase 2/3 Completed
74 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡